新型止血肽溶液在内镜黏膜下剥离术中的疗效与安全性:多中心随机对照试验
这项多中心、开放标签、随机对照试验纳入227例拟行内镜黏膜下剥离术的胃和直肠上皮肿瘤患者,比较新型止血肽TDM-621与常规止血方法处理术中渗血的效果。TDM-621组止血钳凝固次数均数1.0±1.4次,显著低于对照组的4.9±5.2次(P<0.001);仅用TDM-621达到止血的比例为62.2%,平均剂量1.75±2.14 mL。TDM-621组与对照组≥3级不良事件发生率分别为6.2%和5.0%。
要点
- TDM-621组止血钳凝固次数均数1.0±1.4次,显著低于对照组4.9±5.2次(P<0.001)。
- 仅用TDM-621即达到止血的比例为62.2%,平均剂量1.75±2.14 mL。
- TDM-621组与对照组≥3级不良事件发生率分别为6.2%和5.0%。
核心结论
- TDM-621是处理胃和直肠内镜黏膜下剥离术术中渗血的有用且易于操作的止血肽,未发现严重安全性问题。
研究设计与样本
- 多中心、开放标签、随机对照试验,纳入227例拟行内镜黏膜下剥离术的胃和直肠上皮肿瘤患者。
- 术中水刀冲洗难以识别渗血来源且需止血钳止血者随机分为TDM-621组和对照组。
- TDM-621组以TDM-621止血,必要时辅以止血钳凝固止血;对照组以止血钳止血。
- 主要终点为盲法独立评审委员会判定的止血钳凝固次数均数。
主要发现
- 止血钳凝固次数均数TDM-621组为1.0±1.4次,对照组为4.9±5.2次,TDM-621组较对照组显著减少(P<0.001)。
- 仅用TDM-621达到止血的比例为62.2%。
- TDM-621平均剂量为1.75±2.14 mL。
- ≥3级不良事件发生率TDM-621组为6.2%,对照组为5.0%。
关键数值与推荐
- 主要终点止血钳凝固次数均数TDM-621组1.0±1.4次 vs 对照组4.9±5.2次(P<0.001)。
- 仅用TDM-621达到止血的比例62.2%。
- TDM-621平均剂量1.75±2.14 mL。
- ≥3级不良事件发生率TDM-621组6.2% vs 对照组5.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To compare the effectiveness of the novel hemostatic peptide, TDM-621, with that of conventional hemostatic methods in treating intraoperative blood oozing during endoscopic submucosal dissection (ESD). METHODS: This multicenter, open-label, randomized controlled trial involved 227 patients with gastric and rectal epithelial tumors in whom ESD was indicated. Patients in whom the source of blood oozing was difficult to identify with waterjet washing during the procedure and required hemostasis with hemostatic forceps were randomly assigned to the TDM-621 and control groups. The TDM-621 group (in which hemostasis was achieved with TDM-621, followed by coagulation hemostasis with hemostatic forceps, as needed) was compared with the control group (in which hemostasis was achieved with hemostatic forceps). The primary end point was the mean number of coagulations with hemostatic forceps, determined by a blinded independent review committee. The secondary end points were the rate of achievement of hemostasis with only TDM-621, the dosage of TDM-621, and adverse events in the TDM-621 group. RESULTS: The mean number of coagulations with hemostatic forceps was significantly reduced in the TDM-621 group (1.0 ± 1.4) compared with that in the control group (4.9 ± 5.2) ( P < 0.001). The rate of hemostasis achievement with only TDM-621 was 62.2%; the mean dosage of TDM-621 was 1.75 ± 2.14 mL. The rates of grade ≥3 adverse events were 6.2% and 5.0% in the TDM-621 and control groups, respectively. DISCUSSION: TDM-621 is a useful, easily operable hemostatic peptide for treatment of blood oozing during gastric and rectal ESD, with no serious safety concerns.
引用
- Uraoka T, Uedo N, Oyama T, et al. Efficacy and Safety of a Novel Hemostatic Peptide Solution During Endoscopic Submucosal Dissection: A Multicenter Randomized Controlled Trial. Am J Gastroenterol. 2022. PMID: 36449784. doi:10.14309/ajg.0000000000002060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。